文献速递MDS 与骨髓增殖性肿瘤白血病

EZH2突变型骨髓增生异常/骨髓增殖性肿瘤患者的分子特征

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
PubMed 文献 · Leukemia · 2017-06-19

该研究对41例EZH2突变的骨髓增生异常/骨髓增殖性肿瘤(MDS/MPN)患者进行靶向深度二代测序、集落形成祖细胞实验和转录组分析,并在MDS来源的F-36P、MOLM-13和OCI-M2细胞中通过稳定shRNA介导EZH2下调研究EZH2特异性改变。靶向NGS共发现190个个体突变,EZH2突变常与TET2(58%)、RUNX1(40%)和ASXL1(34%)突变共存。集落实验提示EZH2突变多为白血病发生的早期事件并显示复杂突变层级。

要点

  • 41例EZH2突变MDS/MPN患者经靶向深度NGS共检出190个个体突变。
  • EZH2突变常与TET2(58%)、RUNX1(40%)和ASXL1(34%)突变共存。
  • 集落实验提示EZH2突变多为白血病发生的早期事件并显示复杂突变层级。

核心结论

  • EZH2突变型MDS/MPN具有复杂突变模式,EZH2突变常与TET2、RUNX1和ASXL1突变共存,且多为白血病发生的早期事件。
  • 患者转录组与EZH2下调细胞系数据比较发现若干新EZH2靶基因,在细胞系与患者间呈相反及单向调控。
  • CXXC5、ETS1和VAV3等基因既往被提示在白血病发生中起作用,其在MDS/MPN中的确切作用需进一步研究。

研究设计与样本

  • 对41例EZH2突变的MDS/MPN患者队列进行靶向深度二代测序(NGS)、集落形成祖细胞实验和转录组分析。
  • 在MDS来源的F-36P、MOLM-13和OCI-M2细胞中进行稳定shRNA介导的EZH2下调以研究EZH2特异性改变。

主要发现

  • 靶向NGS共发现190个个体突变,显示复杂突变模式。
  • EZH2突变常与TET2(58%)、RUNX1(40%)和ASXL1(34%)突变共存。
  • 集落实验提示EZH2突变多为白血病发生的早期事件,并显示复杂突变层级。
  • 基因表达数据揭示EZH2野生型与突变型患者间存在若干差异表达基因,包括已知EZH2靶基因。
  • 患者转录组与EZH2下调细胞系数据比较发现若干基因作为新EZH2靶点,在细胞系与患者间呈相反及单向调控。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • CXXC5、ETS1和VAV3等基因在MDS/MPN中的确切作用需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in the epigenetic regulator gene EZH2 are frequently observed in patients with myelodysplastic/myeloproliferative neoplasms (MDS/MPN; 10-13%) and are associated with a poor outcome. To gain more insight into EZH2 pathology, we sought to genetically characterize a cohort of 41 EZH2-mutated MDS/MPN patients using targeted deep next-generation sequencing (NGS), colony-forming progenitor assays and transcriptome analysis. Stable short hairpin RNA (shRNA)-mediated downregulation of EZH2 was performed in MDS-derived F-36P, MOLM-13 and OCI-M2 cells to study EZH2-specific changes. Targeted NGS revealed a complex pattern of mutations with a total of 190 individual mutations. EZH2 mutations frequently co-occur with TET2 (58%), RUNX1 (40%) and ASXL1 (34%) mutations. Colony assays indicated EZH2 mutations to be mostly early events in leukemogenesis and showed a complex mutational hierarchy. Gene expression data revealed a number of differently expressed genes between EZH2 wild-type and mutant patients including known EZH2 targets. Comparison of patient transcriptome to EZH2-downregulated cell line data revealed several genes as novel EZH2 targets, showing opposite as well as unidirectional regulation between cell lines and patients. Some genes, such as CXXC5, ETS1 and VAV3 have previously been implied to have a role in leukemogenesis. Their precise role in MDS/MPN needs to be further investigated.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Rinke J, Müller JP, Blaess MF, et al. Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms. Leukemia. 2017. PMID: 28626218. doi:10.1038/leu.2017.190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。